Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

C/EBPalpha triggers proteasome-dependent degradation of cdk4 during growth arrest.

Wang H, Goode T, Iakova P, Albrecht JH, Timchenko NA.

EMBO J. 2002 Mar 1;21(5):930-41.

2.

Invasive melanoma in Cdk4-targeted mice.

Sotillo R, García JF, Ortega S, Martin J, Dubus P, Barbacid M, Malumbres M.

Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13312-7. Epub 2001 Oct 23.

3.

Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis.

Miliani de Marval PL, Gimenez-Conti IB, LaCava M, Martinez LA, Conti CJ, Rodriguez-Puebla ML.

Am J Pathol. 2001 Jul;159(1):369-79.

4.

Specific protection against breast cancers by cyclin D1 ablation.

Yu Q, Geng Y, Sicinski P.

Nature. 2001 Jun 28;411(6841):1017-21.

PMID:
11429595
5.

Small molecule modulators of cyclin-dependent kinases for cancer therapy.

Senderowicz AM.

Oncogene. 2000 Dec 27;19(56):6600-6. Review.

6.

Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein.

Ikuta M, Kamata K, Fukasawa K, Honma T, Machida T, Hirai H, Suzuki-Takahashi I, Hayama T, Nishimura S.

J Biol Chem. 2001 Jul 20;276(29):27548-54. Epub 2001 May 2.

7.

Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism.

Bienvenu F, Gascan H, Coqueret O.

J Biol Chem. 2001 May 18;276(20):16840-7. Epub 2001 Feb 20.

8.

Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.

Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K, Shiraki K.

Oncogene. 2000 Jul 6;19(29):3225-34.

9.

Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.

Lam PY, Di Tomaso E, Ng HK, Pang JC, Roussel MF, Hjelm NM.

Br J Neurosurg. 2000 Feb;14(1):28-32.

PMID:
10884881
10.

Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF.

Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC.

Cell. 2000 Mar 31;101(1):79-89.

11.

Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours.

Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD, Tallini G.

J Pathol. 2000 Apr;190(5):531-6.

PMID:
10727978
12.

Preclinical and clinical development of cyclin-dependent kinase modulators.

Senderowicz AM, Sausville EA.

J Natl Cancer Inst. 2000 Mar 1;92(5):376-87. Review.

PMID:
10699068
13.

Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations.

Corcoran MM, Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP, Platt C, Tsui LC, Scherer SW, Oscier DG.

Oncogene. 1999 Nov 4;18(46):6271-7.

14.

Increased expression of mutated Ha-ras during premalignant progression in SENCAR mouse skin.

Rodriguez-Puebla ML, LaCava M, Bolontrade MF, Russell J, Conti CJ.

Mol Carcinog. 1999 Nov;26(3):150-6.

PMID:
10559789
15.
16.

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.

Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, Kiyokawa H.

Mol Cell Biol. 1999 Oct;19(10):7011-9.

17.

Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells.

Sánchez-Beato M, Camacho FI, Martínez-Montero JC, Sáez AI, Villuendas R, Sánchez-Verde L, García JF, Piris MA.

Blood. 1999 Jul 15;94(2):765-72.

18.

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.

Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, Barbacid M.

Nat Genet. 1999 May;22(1):44-52.

19.

ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development.

Rodriguez-Puebla ML, Robles AI, Conti CJ.

Mol Carcinog. 1999 Jan;24(1):1-6. Review.

PMID:
10029404
20.

Supplemental Content

Support Center